2. Neuronal Signaling
  3. Amyloid-β
  4. Donanemab

Donanemab  (Synonyms: LY3002813)

Cat. No.: HY-P99859 Purity: ≥99%
Data Sheet
SDS
COA
Technical Support

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.

For research use only. We do not sell to patients.

CAS No. : 1931944-80-7

Size Price Stock Quantity
1 mg USD 350 In-stock
5 mg USD 910 In-stock
10 mg USD 1450 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it April 2 by noon. Order within 20 hrs 11 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Donanemab Featured Recommendations:

Donanemab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Donanemab is a humanized IgG1 antibody directed at an N-terminal pyroglutamate Aβ epitope that is present only in established plaques. Donanemab is specific for this epitope and shows no off-target binding to other Aβ species, neurotransmitters, or their receptors[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Donanemab Related Antibodies
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT05738486Eli Lilly and Company
Alzheimer´s Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Neurodegenerative Diseases|Neurocognitive Disorders|Mental Disorders
February 28, 2023Phase 3
NCT03367403Eli Lilly and Company
Alzheimer Disease
December 18, 2017Phase 2
NCT05026866Eli Lilly and Company
Alzheimer Disease
August 27, 2021Phase 3
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Donanemab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation

Purity: ≥99%

Data Sheet (255 KB) SDS (251 KB)

COA (231 KB)SDS-PAGE (157 KB)SEC-HPLC (105 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Donanemab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Donanemab1931944-80-7LY3002813LY 3002813LY-3002813Amyloid-ββ-amyloid peptideAβAbetahumanized IgG1 monoclonal antibodyAlzheimer's diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Donanemab
Cat. No.:
HY-P99859
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.